Not much to hang your hopes on here, it looks like a double top with the second top being a head and shoulders. The divergence between RSI and price at the two tops is tenuous, but I wish it wasn't even possible to consider it. As far as the financial statement is concerned, it says the IPO was in 2015 and I guess it's standard procedure for biotechs to lose money for some years but you'd think that a solid company would wait to go public until they were nearly profitable, wouldn't you? Anyway, I'm down 26% from where I bought in, that's the limit for me really and I'd have bailed today except for the small rise... Thanks for any perspective!
Comment:
Wow, it really nose-dived soon after that post.